A promising human clinical trial on four patients may pave the way for a new treatment of glioblastoma, an aggressive form of brain cancer. Researchers from the University of Florida in the US developed an mRNA cancer vaccine which triggers the immune system to target the tumour. Approximately 19,000 individuals in the EU are believed to be affected by this condition annually. The approach to treating glioblastoma has seen little evolution since the early 2000s, primarily relying on chemotherapy, radiotherapy, and surgical interventions. The average survival duration for patients diagnosed wit…